Sunday, November 28, 2021 10:36:44 PM
Diver, please correct me if I'm wrong, but I believe the FlaskWork device takes roughly the same amount of time for each batch of the vaccine. The big difference is ten or more machines can probably be put in the space of a single clean room needed to produce a single batch at a time.
I'd also like to bring up CRL. We all seem to deal with the capability being developed at Sawston, but I've heard no ones estimate of how many batches of the vaccine CRL is capable of making simultaneously. As I understand it, without the FlaskWork device an individual clean room is needed for slightly over a week for each batch. I believe that CRL has lots of clean rooms, the question is, how many will they devote to the production of DCVax-L. I believe their capacity will greatly exceed that of Sawston when all of it has been built out.
I'd also like to know people's thoughts on the Journal having difficulty getting documentation needed to do the peer review. Perhaps I'm wrong, but it would seem to me that everything they need should be found in all the information the company is working with in creating the BLA. If this isn't the case, why can't the company duplicate it and provide it to the peer reviewers.
Gary
I'd also like to bring up CRL. We all seem to deal with the capability being developed at Sawston, but I've heard no ones estimate of how many batches of the vaccine CRL is capable of making simultaneously. As I understand it, without the FlaskWork device an individual clean room is needed for slightly over a week for each batch. I believe that CRL has lots of clean rooms, the question is, how many will they devote to the production of DCVax-L. I believe their capacity will greatly exceed that of Sawston when all of it has been built out.
I'd also like to know people's thoughts on the Journal having difficulty getting documentation needed to do the peer review. Perhaps I'm wrong, but it would seem to me that everything they need should be found in all the information the company is working with in creating the BLA. If this isn't the case, why can't the company duplicate it and provide it to the peer reviewers.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
